Details for New Drug Application (NDA): 215276
✉ Email this page to a colleague
NDA 215276 describes HABITROL, which is a drug marketed by Dr Reddys Labs Sa and is included in two NDAs. It is available from sixteen suppliers. Additional details are available on the HABITROL profile page.
The generic ingredient in HABITROL is nicotine polacrilex. There are two drug master file entries for this compound. Sixty suppliers are listed for this compound. Additional details are available on the nicotine polacrilex profile page.
The generic ingredient in HABITROL is nicotine polacrilex. There are two drug master file entries for this compound. Sixty suppliers are listed for this compound. Additional details are available on the nicotine polacrilex profile page.
Summary for 215276
| Tradename: | HABITROL |
| Applicant: | Dr Reddys Labs Sa |
| Ingredient: | nicotine polacrilex |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | OTC | Dosage: | TROCHE/LOZENGE;ORAL | Strength | EQ 2MG BASE | ||||
| Approval Date: | Jul 17, 2025 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | OTC | Dosage: | TROCHE/LOZENGE;ORAL | Strength | EQ 4MG BASE | ||||
| Approval Date: | Jul 17, 2025 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
